IGM Biosciences Inc (IGMS) News

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Form 4 - Statement of changes in beneficial ownership of securities

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Form 4 - Statement of changes in beneficial ownership of securities

Amended Statement of Beneficial Ownership (sc 13d/a)

    UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE...

Amended Statement of Beneficial Ownership (sc 13d/a)

    SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13D (Rule 13d-102)   INFORMA...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Current Report Filing (8-k)

0001496323false00014963232023-06-232023-06-23   UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549  ...

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Free Writing Prospectus pursuant to Rule 433 dated June 22, 2023 Relating to the Preliminary...

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced...

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Free Writing Prospectus pursuant to Rule 433 dated June 21, 2023 Registration Statement...

IGM Announces Proposed Public Offering and Concurrent Private Placement

MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced...

Current Report Filing (8-k)

false 0001496323 0001496323 2023-06-02 2023-06-02     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549  ...

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

  – Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median...

IGM Biosciences to Present at the Jefferies Healthcare Conference

MOUNTAIN VIEW, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a...